Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
9.66
+0.16 (1.68%)
At close: Nov 22, 2024, 4:00 PM
9.88
+0.22 (2.28%)
After-hours: Nov 22, 2024, 4:19 PM EST
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $141.52M in the quarter ending September 30, 2024, with 36.73% growth. This brings the company's revenue in the last twelve months to $493.67M, up 32.58% year-over-year. In the year 2023, Amicus Therapeutics had annual revenue of $399.36M with 21.30% growth.
Revenue (ttm)
$493.67M
Revenue Growth
+32.58%
P/S Ratio
5.93
Revenue / Employee
$954,876
Employees
517
Market Cap
2.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
Dec 31, 2019 | 182.24M | 90.99M | 99.72% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Surgery Partners | 2.99B |
Concentra Group Holdings Parent | 1.88B |
LivaNova | 1.24B |
LifeStance Health Group | 1.21B |
Warby Parker | 742.53M |
Inari Medical | 574.50M |
Vericel | 226.84M |
SpringWorks Therapeutics | 135.49M |
FOLD News
- 11 days ago - NCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial Rights - GlobeNewsWire
- 17 days ago - Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 - GlobeNewsWire
- 26 days ago - Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewsWire
- 4 weeks ago - American Citizens Abroad (ACA) joins amicus brief supporting voting by U.S. citizens overseas - GlobeNewsWire
- 4 weeks ago - 3 Attractive Biotechs With Recent Positives - Seeking Alpha
- 5 weeks ago - Amicus: Teva Settlement Clears Revenue Path Forward For Galafold - Seeking Alpha
- 5 weeks ago - Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug - Benzinga